Purdue Pharma Granted an Additional 18-Day Extension, Opioid Crisis Compensation Still Unresolved, Sackler Family Lawsuit Stalemate
Purdue Pharma on Thursday received approval from U.S. Bankruptcy Judge Sean Lane for an 18-day extension of the lawsuit against members of its owner, the Sackler family. The decision came against the backdrop of Purdue convincing a judge that extending settlement talks would help reach a comprehensive resolution. Purdue Pharma's painkiller OxyContin has been accused of sparking the opioid addiction crisis in the United States.
In June, the U.S. Supreme Court overturned Purdue's previous bankruptcy settlement, ruling that bankruptcy courts could not dissolve legal claims against non-debtors such as the Sackler family without the consent of someone who could Sue. The Sacklers did not file for bankruptcy, but the Supreme Court ruling means they cannot go through Purdue's bankruptcy process to avoid lawsuits over their role in the deadly opioid epidemic in the United States.
Nearly five years after its bankruptcy, Purdue has had to restart the settlement process because of the Supreme Court ruling, jeopardizing billions of dollars that the company and the Sackler family had promised to pay out to address the damage caused by the crisis. Purdue attorney Marshall Huebner said the company plans to keep as much of its previous plan as possible.
Most U.S. state attorneys general, as well as a coalition of counties and other local governments that have brought legal action against Purdue and the Sackler family, have supported a short-term extension. A court-appointed creditor committee also supported the extension and promised to Sue the Sackler family if mediation failed.
However, some governments have objected to the 18-day negotiating window as a "slippery slope," noting that Purdue has used a "short-term" extension to prevent anyone from filing a lawsuit against the Sackler family since its bankruptcy began in 2019. Hunter Schkolnik, an attorney for Nassau County, said they had received extension request after extension request, but nothing had been documented to indicate that a deal was imminent.
Purdue filed for Chapter 11 bankruptcy in 2019 to settle its debts, almost all stemming from thousands of lawsuits alleging that OxyContin helped spark the opioid epidemic. The epidemic has led to more than half a million overdose deaths in the United States in two decades. State and local governments and individual plaintiffs have filed lawsuits against Purdue and members of the Sackler family, accusing them of exacerbating the opioid crisis through deceptive marketing of painkillers. Purdue admitted to false branding and fraud charges related to the marketing of OxyContin in 2007 and 2020, while family members denied wrongdoing but expressed regret that OxyContin "accidentally became part of the opioid crisis."
The case was filed in the United States Bankruptcy Court for the Southern District of New York at number 19-bk-23649. Purdue was represented by Marshall Huebner of Davis Polk & Wardwell, The creditor committee was represented by Arik Preis and Mitchell Hurley of Akin Gump Strauss Hauer & Feld.
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
FDA Color Policy Uncertainty Opens a New Chapter for Food Ingredient Reform
-
Bayer and Syngenta Score Consecutive Regulatory and Legal Wins in the U.S.
-
South Korea Expands Mandatory GMO Labeling to Highly Processed Foods
-
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
-
Four Fine Chemical Units of Huajin Aramco Project – HDPE, EO/EG, etc. – Reach Mechanical Completion
-
关于将二氟乙咪酯等16种物质列入《非药用类麻醉药品和精神药品目录》的公告 Announcement on the Inclusion of 16 Substances including Difluoroetomidate in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
Recommend Reading
-
US Tariff Pressure on Canada Raises Risks for North American Chemical Supply Chains
-
FDA Lifts Administrative Stay, Restoring Red No. 3 Ban Timeline for Food and Ingested Drugs
-
UK Proposes Anti-Dumping Duties of Up to 63.66% on Chinese Rutile Titanium Dioxide
-
U.S. Sets Preliminary 107.57% Countervailing Rate on Chinese Rubber Accelerator CBS
-
U.S. Finds Methionine Dumping Could Recur, With Japan Margin Up to 76.50%
-
Cytosine: Structure, DNA Pairing, and Role in Genetics
-
Brent Crude Returns to $100 as Conflict Escalation & Tightening Supply and Demand Reshape New Stage Highs for Oil Prices
-
Business Society’s MTBE Market Outlook on September 10, 2026: Relatively Strong Fluctuations
-
Bovine Serum Albumin (BSA): Role in Cell Culture & Laboratory Applications
-
Business Society’s MTBE Market Outlook on September 9, 2026: Weak Rebound
- Hot Searches
- where can i buy reta peptide
- naphthenic rubber processing oil market
- kerosene average price
- silicon tetrafluoride
- price of retatrutide
- bio based succinic acid
- glycerin pricing
- buy adrenochrome
- starch safety data sheet
- where can you buy sulfur hexafluoride
- boric acid 99
- ammonium sulphate fertilizer price